Aspargo Labs is a pharmaceutical startup that specializes in the production and distribution of an oral spray suspension formulation of sildenafil citrate, the active ingredient in VIAGRA®. This innovative product offers a novel and convenient method of administration for this commonly prescribed medication for erectile dysfunction. Instead of conventional pills or tablets, Aspargo Labs has developed a spray format, making it easier and more convenient for users.

The company operates in the pharmaceutical market, serving clients who require erectile dysfunction medication. Aspargo Labs has secured the exclusive commercialization rights to Sildenafil Oral Spray in the United States and more than 75 countries across Europe, Asia, the Middle East, South America, the United Kingdom, and Canada. This was achieved through a patent licensing agreement with Farmalíder S.A., a pharmaceutical company based in Madrid, Spain.

Aspargo Labs' business model revolves around the production and distribution of its unique product. The company generates revenue through the sales of its Sildenafil Oral Spray. It has been actively expanding its market reach, as evidenced by its regulatory approval to market the spray in Germany, Ireland, the Netherlands, and its expansion into Latin America and the Middle East.

In terms of research and development, Aspargo Labs has been conducting bioavailability and food-effect studies for its Sildenafil Oral Spray, with the U.S. FDA clearing its Investigational New Drug Application. This indicates the company's commitment to ensuring the safety and efficacy of its product.

Keywords: Aspargo Labs, Sildenafil Oral Spray, erectile dysfunction, pharmaceutical market, patent licensing agreement, Farmalíder S.A., product commercialization, market expansion, bioavailability studies, Investigational New Drug Application.